Loading...
NPI 1073962288 · Coral Springs, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Forensic Stat Laboratory Inc is a clinical medical laboratory provider located in Coral Springs, Florida. This profile covers 1 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Forensic Stat Laboratory Inc |
| Address | 10438 W Atlantic Blvd |
| City | Coral Springs |
| State | FL |
| ZIP | 33071 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 8, 2016 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $11.6M |
| Medicaid | $62.6K |
Taxonomy and service mix indicate a clinical diagnostic laboratory primarily billing for COVID-19 testing: the provider is listed as a Clinical Medical Laboratory and its Medicare revenue is driven entirely by K1034 (provision of nonprescription self‑administered COVID-19 tests), while Medicaid billing includes nucleic acid detection codes U0003 and U0005 consistent with lab PCR workflows. This combination of K1034 on Medicare and U0003/U0005 on Medicaid shows parallel streams for self‑administered antigen/kit provisioning and laboratory‑performed molecular testing.
Medicare revenue is highly concentrated: the precomputed top‑3 Medicare codes account for 100.0% of Medicare revenue, and K1034 alone represents $11.8M of Medicare income with 985.4K claims. That single‑code concentration means Medicare activity is essentially mono‑line and dominated by the nonprescription self‑test pathway.
The provider is effectively Medicare‑centric on scale: lifetime Medicare revenue is $11.6M versus lifetime Medicaid revenue of $62.6K, so Medicare drives nearly all financial activity reported. Analysts should treat this entity as a Medicare‑scale operator with only a modest Medicaid footprint rather than a balanced payer mix.
Medicaid billing is also concentrated in a small set of codes: the top 3 Medicaid codes account for 99.4% of Medicaid revenue, with U0003 contributing $58.8K (92.1% of Medicaid revenue). U0003’s presence indicates the provider performs or bills for high‑throughput nucleic acid detection for SARS‑CoV‑2 in the Medicaid population, but overall Medicaid dollars remain small compared with Medicare.
Competitive standing is bifurcated by payer and code: for Medicare K1034 the provider ranks #45 of 30143 (100th percentile; extreme outlier), marking it as a national high‑volume outlier for that code. By contrast, its Medicaid U0003 activity ranks #133 of 320 in‑state (59th percentile; typical), indicating a modest in‑state position on the PCR testing side even though U0003 dominates this provider’s modest Medicaid revenue.
Claims and reimbursement patterns point to different unit economics across payers: Medicare K1034 shows 985.4K claims at $12 avg paid/claim and accounts for $11.8M revenue, while Medicaid shows 1.1K claims for U0003 at $53 avg paid/claim and 2.6K claims for K1034 at $1 avg paid/claim. This suggests the provider’s Medicare volume is driven by very high unit counts of a lower per‑claim paid, nonprescription test product, whereas Medicaid revenue is dominated by fewer, higher‑paid PCR claims.
Operational tenure and timing: the NPI was enumerated 2016-06-08 (~10 years ago), so the provider has an established enrollment history, and the present revenue profile—heavily concentrated in COVID‑related codes—suggests the practice’s recent billing scale is tied closely to pandemic testing activity rather than a broad, diversified lab portfolio.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 985,440 | $10 | $11.8M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 4 | 2,890 | 600 | $10 | $68.5K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,110 | $50 | $58.8K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2,560 | $1 | $2.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1,070 | $1 | $2.1K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 20 | $20 | $360 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 940 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 133 | 320 | 750 | $40 | $232.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 73 | 180 | 630 | $10 | $38K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 596 | 640 | 340 | $10 | $25.2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 44 | 160 | 100 | $10 | $8.8K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 9 | 240 | 60 | $1 | $330 |
Other providers in the same ZIP code as Forensic Stat Laboratory Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Broward Kidney Centers Of Coral Springs LLC | FL | End-Stage Renal Disease (ESRD) Treatment Clinic/Center | $0 | $18.7M |
| Allied Healthcare Solutions LLC | FL | Nursing Care Agency | $0 | $8.2M |
| Justin Rubin | FL | Dermatology Physician | $1.3M | $0 |
| Ivette Caballero | FL | Family Nurse Practitioner | $561.7K | $0 |
| Alexander Shapsis | FL | Gastroenterology Physician | $192.1K | $94.2K |
| Dawn Scarzella | FL | Urology Physician | $275.1K | $0 |
| Azeem Sachedina | FL | Urology Physician | $117.6K | $0 |
| Alberto Minnocci | FL | Physician Assistant | $25.9K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.